Additional file 3 of The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study

Additional file 3: Figure S2. Subgroup analysis of forest plot of HR for SGLT2i versus glucagon-like peptide-1 receptor agonist (GLP-1RA) among patients with T2D after PSM. Subgroup analysis revealed that use of SGLT2i was associated with a lower risk of new-onset AF compared with use of DPP4i across most subgroups. Use of SGLT2i was associated with greater reductions in new-onset AF events in subgroup including those without concomitant use of sulfonylurea when compared with GLP-1RA (P interaction < 0.01).